ALLIANCES AND COLLABORATIONS (Lilly) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Alliances and Collaborations Statement [Line Items]
Net sales	$ 3,736	$ 5,345	$ 13,430	$ 15,790
Amortization expense - upfront, milestone and other licensing payments			394	261
Other (income)/expense	(50)	(26)	(45)	(195)
Other intangible assets - upfront, milestone and other licensing payments	9,217		9,217		3,124
ERBITUX [Member]
Alliances and Collaborations Statement [Line Items]
Net sales	173	172	531	510
Lilly [Member] | ERBITUX [Member]
Alliances and Collaborations Statement [Line Items]
Net sales	173	172	531	510
Commercialization expense reimbursements to/(from) alliance partner	(4)	(9)	(14)	(12)
Lilly [Member] | ERBITUX [Member] | North America [Member]
Alliances and Collaborations Statement [Line Items]
Distribution fee, percentage of net sales	39.00%		39.00%
Distribution fees and royalty expense	71	72	220	212
Lilly [Member] | ERBITUX [Member] | Japan [Member] | Commercialization Profit Sharing Income Expense [Member]
Alliances and Collaborations Statement [Line Items]
Other (income)/expense	(9)	(9)	(28)	(24)
Lilly [Member] | necitumumab [Member]
Alliances and Collaborations Statement [Line Items]
Research and development reimbursements to/(from) collaboration partner	5	4	13	10
Lilly [Member] | necitumumab [Member] | Development Costs For United States Studies [Member]
Alliances and Collaborations Statement [Line Items]
Funding of development costs, percentage	55.00%		55.00%
Lilly [Member] | necitumumab [Member] | Development Costs For Global Studies [Member]
Alliances and Collaborations Statement [Line Items]
Funding of development costs, percentage	27.50%		27.50%
Lilly [Member] | necitumumab [Member] | Development Costs For Japan Studies [Member]
Alliances and Collaborations Statement [Line Items]
Funding of development costs, percentage	50.00%		50.00%
Lilly [Member] | ERBITUX And Necitumumab [Member] | Upfront, milestone and other licensing payments [Member]
Alliances and Collaborations Statement [Line Items]
Total upfront, milestone and other licensing payments	500		500
Amortization expense - upfront, milestone and other licensing payments	9	9	28	28
Other intangible assets - upfront, milestone and other licensing payments	221		221		249
Lilly [Member] | BYETTA And BYDUREON [Member] | Non United States [Member]
Alliances and Collaborations Statement [Line Items]
Maximum amount payable to alliance partner for losses			$ 60
Lilly and Merck KGaA [Member] | ERBITUX [Member] | Japan [Member]
Alliances and Collaborations Statement [Line Items]
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner.	50.00%		50.00%